Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05357079 · ClinicalTrials.gov registry record · Early Phase 1

Impact of Topical Tranexamic Acid on Pre- and Post-operative Hemoglobin/Hematocrit

A Early Phase 1 study, sponsored by University of Cincinnati.

Completed
Registry status
Early Phase 1
Development phase
94
Enrollment target

NCT05357079 is a Early Phase 1 study that has completed, run by University of Cincinnati. The registered enrollment target is 94 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05357079, a Early Phase 1 study, has completed, sponsored by University of Cincinnati.

COMPLETED
Registry status
Early Phase 1
Development phase
94 participants
Enrollment target

Study Summary

This multi-center, prospective study will evaluate the use of topical tranexamic acid (TXA - Cyklokapron; Pfizer, New York, NY) on pre-operative and post-operative hemoglobin (Hb)/hematocrit (Hct) in patients undergoing operative repair of isolated posterior wall (PW) acetabular fractures.

Interventions

  • DRUG Normal saline
  • DRUG Tranexamic Acid

Trial Details

FieldValue
Enrollment Target 94 participants
Start Date 2017-08-25
Est. Completion 2024-12-02
Phase Early Phase 1

Sponsor

University of Cincinnati

245 total trials

What the Registry Record Tells You About NCT05357079

The ClinicalTrials.gov registry entry for NCT05357079 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.

NCT05357079 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05357079 about?

NCT05357079 is a clinical study titled "Impact of Topical Tranexamic Acid on Pre- and Post-operative Hemoglobin/Hematocrit". This multi-center, prospective study will evaluate the use of topical tranexamic acid (TXA - Cyklokapron; Pfizer, New York, NY) on pre-operative and post-operative hemoglobin (Hb)/hematocrit (Hct) in patients undergoing operative repair of isolated posterior wall (PW) acetabular fractures.

What is the current status of trial NCT05357079?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 94 participants. The study started on 2017-08-25. Estimated completion is 2024-12-02.

What interventions are being tested in trial NCT05357079?

The interventions under investigation include: Normal saline (DRUG), Tranexamic Acid (DRUG).

Who is sponsoring clinical trial NCT05357079?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.